SPEN inactivation drives resistance to androgen receptor pathway inhibitors in metastatic prostate cancer.

Steven Blinka¹, Sonali Arora¹, Dmytro Rudoy², Anika Gowda¹, Peter Yong³, Yisoo Hwang¹, Michael D Nyquist¹, Ryon Graf⁴, Gerald Li⁵, Peter S Nelson¹, Michael T Schweizer³, Andrew C Hsieh¹

¹Fred Hutch Cancer Center Seattle, WA United States.

²Fred Hutch Cancer Center United States.

³Fred Hutch Cancer Center Seattle United States.

⁴Foundation Medicine San Diego, CA United States.

⁵Foundation Medicine (United States) Cambridge, MA United States.

PubMed DOI

Abstract

PURPOSE: Treatment intensification with androgen receptor pathway inhibitors (ARPIs) has become the standard of care for patients with metastatic prostate cancer. However, there remains an unmet need to identify biomarkers for treatment resistance. Here, we identify SPEN inactivation as a driver of ARPI resistance. EXPERIMENTAL DESIGN: Pre-clinical studies were performed in LNCaP and VCaP cell li…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.